Catalent, Inc. (NYSE:CTLT) Stake Lessened by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC trimmed its stake in shares of Catalent, Inc. (NYSE:CTLT) by 33.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,986 shares of the company’s stock after selling 10,983 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Catalent were worth $1,332,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the 2nd quarter valued at approximately $42,000. Mather Group LLC. bought a new stake in Catalent during the first quarter valued at $52,000. Longfellow Investment Management Co. LLC raised its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC lifted its position in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in shares of Catalent by 4,466.7% in the 1st quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock valued at $77,000 after buying an additional 1,340 shares during the period.

Insiders Place Their Bets

In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Catalent news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,410 shares of company stock worth $732,680. 0.31% of the stock is owned by corporate insiders.

Catalent Stock Down 0.6 %

Shares of Catalent stock opened at $60.28 on Thursday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The business’s fifty day moving average price is $60.08 and its two-hundred day moving average price is $57.71. The company has a market capitalization of $10.91 billion, a P/E ratio of -9.88, a PEG ratio of 2.14 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, research analysts forecast that Catalent, Inc. will post 0.95 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. StockNews.com began coverage on shares of Catalent in a research note on Saturday, October 12th. They set a “hold” rating on the stock. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Barclays boosted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Nine equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.